Exact Sciences, Jerry Kelly Team Up
To help raise awareness of colon cancer and the importance of regular screening, professional golfer Jerry Kelly will wear a Cologuard-branded hat for the next two years, Exact Sciences announced…
To help raise awareness of colon cancer and the importance of regular screening, professional golfer Jerry Kelly will wear a Cologuard-branded hat for the next two years, Exact Sciences announced…
Starting July 1, Exact Sciences’ Cologuard will be included for UnitedHealthcare members, the company announced recently. UnitedHealthcare’s network includes 1 million healthcare professionals and 6,000 hospitals across the United States….
In addition to being awarded a Governor’s Export Award, Lucigen was recently honored with the 2017 President’s “E” Award, the highest recognition honoring a U.S. entity for significant contributions to…
Lucigen was recently awarded a Governor’s Export Award at the 53rd Annual Wisconsin International Trade Conference for its extraordinary results in international markets and elevating Wisconsin’s competitiveness in the global…
Story provided by Alex Moe, WisBusiness.com One of the finalists in the Governor’s Business Plan Contest, Cellular Logistics, is making another run at the top prize as it pursues commercialization…
Cellular Dynamics International announced recently that it has signed a distribution agreement with STEMCELL Technologies and a collaboration agreement with the Harvard Stem Cell Institute (HSCI). According to a release,…
Cellectar Biosciences added Douglas Swirsky and Frederick Driscoll to its board of directors, the company announced recently. Swirsky is the president and CEO of GenVec and has worked at Stifel Nicolaus…
Lucigen announced recently it has partnered with Illumina to be the sole distributor of the entire Epicentre Technologies product line. Terms of the deal were not disclosed. The product line…
The Centers for Medicare and Medicaid Services (CMS) is including Exact Sciences’ Cologuard in the 2018 Medicare Advantage Star Ratings program, the company announced recently. “We are pleased that Cologuard has…
Cellectar Biosciences announced today its initiation of a Phase II clinical study of CLR 131 in patients with multiple myeloma and other hemotologic malignancies. According to a release, the study…